Targets › ELAVL1
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Dec 2028.
RNA-binding protein that binds to the 3'-UTR region of mRNAs and increases their stability. Involved in embryonic stem cell (ESC) differentiation: preferentially binds mRNAs that are not methylated by N6-methyladenosine (m6A), stabilizing them, promoting ESC differentiation (By similarity). (UniProt, Q15717)
Open in Phaseline: the race on ELAVL1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Degron Therapeutics | DEG6498 molecular glue inducing HuR (human antigen R) degradation | ELAVL1 | Phase 1 | Malignant Neoplasms | Dec 2028 |
Malignant Neoplasms (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.